FDA approval

IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also…

KENT COUNTY, Mich — A new weight loss drug could soon be joining the growing list of medications…

NEW DELHI: Patients with difficult-to-control high cholesterol could soon have an oral alternative to cholesterol-lowering injections after US…

The FDA clearance, issued under 510(k), expands VELMENI’s dental AI portfolio into three-dimensional cone-beam computed tomography, or CBCT,…

(Representative image) US FDA approves world’s first oral PCSK9 inhibitor (Photo: IANS). NEW DELHI: Patients with difficult-to-control high…

AI-generated image. A familiar hair-loss drug may be getting a major upgrade. A slow-release formulation of minoxidil, one…

While the industry has spent years bracing for and fending off a heavier regulatory hand, what it heard…

KENT COUNTY, Mich. — A new oral version of the weight loss drug Wegovy has been approved by…

The new program complements SuppCo’s TrustScore supplement quality rating system and builds on earlier testing initiatives, which revealed…

Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints News Compass Pathways to Announce…

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients